1. Scrip
  2. >>Business

Stock Watch: Pfizer Caught Between The Pandemic And The Recovery

COVID-19 Gives …And It Takes Away, Disappointing Investors

 
• By Andy Smith

The pandemic is bad for Pfizer’s hospital products and traditional vaccine sales – but recovery is less good for Comirnaty and Paxlovid. Were investors right to be underwhelmed by Pfizer’s 2022 projections?

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

When Pfizer Inc.* released its fourth-quarter 2021 results its stock price initially dropped by 7%, ending the day down by nearly 3% against the virtually unchanged NYSE Arca Pharmaceutical Index. Not for the first time press articles highlighted Pfizer’s profiteering, but for a company that has ticked all the right pandemic boxes, the reaction of its analysts and investors may have felt a little ungrateful.

Pfizer’s reported fourth-quarter revenues grew by 104% over the same period of 2020 but fell by just under 1% on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 
• By Anju Ghangurde

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.